SBIR Phase I: Development and commercialization of organic photocatalysts for light-driven C-N cross-coupling reaction

SBIR 第一阶段：用于光驱动 C-N 交叉偶联反应的有机光催化剂的开发和商业化

• 批准号: 1947053
• 负责人: Chern-Hooi Lim
• 金额: $ 22.5万
• 依托单位: New Iridium
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1947053&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; commercialization; organic

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to develop special metal-free catalysts to dramatically reduce chemical manufacturing costs. In addition, these catalysts significantly expand the range of light-driven reactions, leading to profound advancements in pharmaceuticals, healthcare, agriculture, biology, material science, and other industries. Because light-driven chemical technology predominantly relies on scarce and expensive precious metal catalysts, it is limited today to small-scale R&D applications only. At scale, light-driven technology using metal-free catalysts can greatly reduce chemical manufacturing costs by replacing conventional reactions that rely on expensive precious metals, which are also limited to specific classes of reactions. This new chemistry will significantly expand the possibilities for applications of light-driven chemical technology, leading to novel products and greater consumer access through lower costs.This Small Business Innovation Research (SBIR) Phase I project proposes to demonstrate the suitability of metal-free (organic) photoredox catalysts (PCs) in challenging and important pharmaceutical reactions. Organic PCs are key enablers of photoredox catalysis, an emerging field of chemistry gaining significant traction in drug development. Driven by light absorption, photoredox catalysis offers significant advantages over conventional heat-driven methods (e.g. Pd catalysis), including cost, ease of use, and broadened fields-of-use. Importantly, organic PCs are sustainable and scalable alternatives to predominantly used precious metal PCs, allowing photoredox catalysis to extend to full industrial use, including drug manufacturing. To spur industrial adoption of photoredox catalysis, research objectives include proving feasibility of organic PCs in medicinally important reactions, while expanding substrate scope to include biologically relevant and highly functionalized substrates typically used in drug designs. Photoredox-catalyzed reactions powered by organic PCs will access new chemistries beyond capabilities of conventional heat-driven catalysis. In addition, guided by quantum simulations, new high-performance organic PCs will be developed with unique properties beyond those reported in the literature, unlocking new transformations.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）项目的更广泛的影响/商业潜力是开发特殊的无金属催化剂，以大大降低化学制造成本。此外，这些催化剂大大扩大了光驱动反应的范围，从而导致药物，医疗保健，农业，生物学，材料科学和其他行业的进步。由于光驱动的化学技术主要依赖于稀缺和昂贵的贵金属催化剂，因此今天仅限于小规模的研发应用。根据规模，使用无金属催化剂的轻驱动技术可以通过取代依靠昂贵的贵金属的常规反应来大大降低化学制造成本，这些反应也仅限于特定的反应类别。这种新的化学反应将大大扩大光驱动化学技术的应用的可能性，从而通过较低的成本通过较低的成本提供了新的产品和更大的消费者访问。这项小型企业创新研究（SBIR）I期项目建议证明无金属（有机）光电氧化物催化剂（PC）在具有挑战性和重要的药物反应中的适用性。有机PC是光电毒素催化的关键推动因素，这是一种在药物开发中获得显着牵引力的化学领域。在光吸收的驱动下，Photoredox催化具有比常规热驱动方法（例如PD催化）的显着优势，包括成本，易用性和扩展的使用场。重要的是，有机PC是主要使用的珍贵金属PC的可持续且可扩展的替代品，从而使Photoredox催化可以扩展到包括药物制造在内的全部工业用途。为了刺激工业采用光电毒素催化，研究目标包括证明有机PC在药物重要的反应中的可行性，同时扩大底物范围以包括在药物设计中通常使用的生物学相关和高度功能化的底物。由有机PC提供动力的Photoredox催化反应将获得传统热驱动催化能力的新化学物质。此外，在量子模拟的指导下，将开发新的高性能有机PC，其独特属性以外的独特属性，解锁了新的转换。该奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子优点和更广泛影响的审查标准通过评估来获得支持的。